Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jo Linda Maria Sinagra

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Biomolecules|October 14, 2020
Bullous Pemphigoid: Trigger and Predisposing FactorsFrancesco Moro, Luca Fania, Jo Linda Maria Sinagra, et al.
Frontiers in Medicine|February 6, 2023
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccineAnna Pira, Jo Linda Maria Sinagra, Francesco Moro, et al.
Frontiers in Medicine|January 12, 2024
Pemphigus: trigger and predisposing factorsFrancesco Moro, Jo Linda Maria Sinagra, Adele Salemme, et al.
The Journal of Dermatology|December 1, 2020
Pemphigus vulgaris in two pairs of siblings from two unrelated Italian families: Human leukocyte antigen genotypes, ST18 mutation and immunological profileLuca Fania, Francesco Moro, Elisa De Paolis, et al.
Journal of the American Academy of Dermatology|May 22, 2026
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delayAnna Pira, Adele Salemme, Feliciana Mariotti, et al.
Acta Dermato-Venereologica|June 30, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of PatientsAnna Pira, Martina Merli, Feliciana Mariotti, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Biomolecules|October 14, 2020
Bullous Pemphigoid: Trigger and Predisposing FactorsFrancesco Moro, Luca Fania, Jo Linda Maria Sinagra, et al.
Frontiers in Medicine|February 6, 2023
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccineAnna Pira, Jo Linda Maria Sinagra, Francesco Moro, et al.
Frontiers in Medicine|January 12, 2024
Pemphigus: trigger and predisposing factorsFrancesco Moro, Jo Linda Maria Sinagra, Adele Salemme, et al.
The Journal of Dermatology|December 1, 2020
Pemphigus vulgaris in two pairs of siblings from two unrelated Italian families: Human leukocyte antigen genotypes, ST18 mutation and immunological profileLuca Fania, Francesco Moro, Elisa De Paolis, et al.
Journal of the American Academy of Dermatology|May 22, 2026
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delayAnna Pira, Adele Salemme, Feliciana Mariotti, et al.
Acta Dermato-Venereologica|June 30, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of PatientsAnna Pira, Martina Merli, Feliciana Mariotti, et al.
Pageof 1